2 completed, 2 unknown. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Unknown 2 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow BioSight Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML BST-236, venetoclax - AML, Adult | Phase 1 / Phase 2 | Unknown | BioSight Ltd. | 80 | 2022-08-17 | 2023-04-04 |
| Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS BST-236 - AML, Adult, MDS | Phase 2 | Unknown | BioSight Ltd. | 40 | 2021-11-14 | 2023-03-09 |
| Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy BST-236 - Acute Myeloid Leukemia | Phase 2 | Completed | BioSight Ltd. | 66 | 2018-08-14 | 2023-07-27 |
| Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Astarabine (BST-236) - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | BioSight Ltd. | 20 | 2015-09-01 | 2017-09-27 |
Leukemia, Myeloid, Acute (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
venetoclax (1)
United States (3) · Israel (2)